New delay for the US approval of Centocor's Stelara
This article was originally published in Scrip
Executive Summary
The US approval of Centocor's (Johnson & Johnson) biological psoriasis candidate, Stelara (ustekinumab) has suffered another setback, after the FDA decided to extend the review of its BLA by three months.